Treatment of invasive fungal diseases in cancer patients-Revised 2019 recommendations of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Abstract
Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects.
Leibniz-HKI-Authors
Identifier
doi: 10.1111/myc.13082
PMID: 32236989